Cann Group (ASX:CAN) - Hisse Senedi Fiyatı, Haberler ve Analizler

CAN Stoklara Genel Bakış

Cann Group Limited, iştirakleri ile birlikte Avustralya ve Avrupa'da tıbbi kenevir yetiştiriciliği, üretimi ve satışı yapmaktadır.

Şirket hakkında

CAN temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	0/6

Ödüller

Risk Analizi

Kazançlar son 5 yılda yılda 23.8% oranında azaldı

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Anlamlı bir piyasa değeri yok ( A$20M )

Hissedarlar geçen yıl sulandırıldı

Cann Group Limited Rakipler

Althea Group Holdings

ASX:AGH

AU$24.4m

Rhinomed

ASX:RNO

AU$11.5m

Invion

ASX:IVX

AU$13.5m

Nyrada

ASX:NYR

AU$20.0m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Cann Group
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	AU$0.043
52 Haftanın En Yüksek Seviyesi	AU$0.19
52 Haftanın En Düşük Seviyesi	AU$0.027
Beta	1.09
11 Aylık Değişim	-38.57%
3 Aylık Değişim	13.16%
1 Yıllık Değişim	-62.61%
33 Yıllık Değişim	-84.91%
5 Yıllık Değişim	-95.96%
Halka arzdan bu yana değişim	-93.33%

Son Haberler & Güncellemeler

Cann Group Limited's (ASX:CAN) Price Is Right But Growth Is Lacking After Shares Rocket 36%

Sep 24

Recent updates

Cann Group Limited's (ASX:CAN) Price Is Right But Growth Is Lacking After Shares Rocket 36%

Sep 24

Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For Now

Nov 03

Here's Why We're Not Too Worried About Cann Group's (ASX:CAN) Cash Burn Situation

Feb 23

What Type Of Returns Would Cann Group's(ASX:CAN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Nov 25

One Forecaster Is Now More Bearish On Cann Group Limited (ASX:CAN) Than They Used To Be

Nov 25

Hissedar Getirileri

	CAN	AU Pharmaceuticals	AU Pazar
7D	7.5%	-2.3%	-1.1%
1Y	-62.6%	61.9%	16.1%

Getiri vs. Endüstri: CAN geçen yıl % 61.9 oranında getiri sağlayan Australian Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: CAN geçen yıl % 16.1 oranında getiri sağlayan Australian Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is CAN's price volatile compared to industry and market?
CAN volatility
CAN Average Weekly Movement	23.0%
Pharmaceuticals Industry Average Movement	11.9%
Market Average Movement	8.7%
10% most volatile stocks in AU Market	17.7%
10% least volatile stocks in AU Market	3.6%

İstikrarlı Hisse Senedi Fiyatı: CAN hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: CAN 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 16% dan 23% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2014	n/a	Jenni Pilcher	www.canngrouplimited.com

Cann Group Limited, iştirakleri ile birlikte Avustralya ve Avrupa'da tıbbi kenevir yetiştiriciliği, üretimi ve satışı yapmaktadır. Ayrıca araştırma yapmak ve insani tıbbi ve araştırma amaçlı kenevir yetiştirmek için lisans vermektedir. Şirket 2014 yılında kurulmuştur ve merkezi Port Melbourne, Avustralya'dadır.

Cann Group Limited Temel Bilgiler Özeti

Cann Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CAN temel i̇stati̇sti̇kler
Piyasa değeri	AU$20.16m
Kazançlar(TTM)	-AU$51.24m
Gelir(TTM)	AU$18.36m

1.1x

P/S Oranı

-0.4x

F/K Oranı

CAN aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CAN gelir tablosu (TTM)
Gelir	AU$18.36m
Gelir Maliyeti	AU$12.18m
Brüt Kâr	AU$6.18m
Diğer Giderler	AU$57.42m
Kazançlar	-AU$51.24m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.11
Brüt Marj	33.66%
Net Kâr Marjı	-279.13%
Borç/Özkaynak Oranı	516.6%

CAN uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

CAN Stoklara Genel Bakış

Ödüller

Risk Analizi

Cann Group Limited Rakipler

ASX:AGH

AU$24.4m

ASX:RNO

AU$11.5m

ASX:IVX

AU$13.5m

ASX:NYR

AU$20.0m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million.

Cann Group Limited's (ASX:CAN) Price Is Right But Growth Is Lacking After Shares Rocket 36%

Cann Group Limited, Annual General Meeting, Oct 28, 2024

Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023)

Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024

Cann Group Limited Appoints Jenni Pilcher as Managing Director

Recent updates

Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million.

Cann Group Limited's (ASX:CAN) Price Is Right But Growth Is Lacking After Shares Rocket 36%

Cann Group Limited, Annual General Meeting, Oct 28, 2024

Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023)

Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024

Cann Group Limited Appoints Jenni Pilcher as Managing Director

Less than half of directors are independent

Cann Group Limited's (ASX:CAN) Low P/S No Reason For Excitement

New major risk - Financial position

Cann Group Limited Appoints Tony Di Pietro as Joint Company Secretary of Head of Legal and Regulatory Affairs

A Piece Of The Puzzle Missing From Cann Group Limited's (ASX:CAN) Share Price

Cann Group Limited Announces Resignation of Deborah Ambrosini as Chief Financial Officer, Effective December 22, 2023

Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million.

Cann Group Limited, Annual General Meeting, Oct 26, 2023

Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)

New minor risk - Financial data availability

Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million.

Cann Group Limited Provides Revenue Guidance for the Year Ended June 30, 2023

Cann Group (ASX:CAN) Is Making Moderate Use Of Debt

First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)

Cann Group Limited Announces Preliminary Results from Their Phase 3 Clinical Trail

Cann Group Limited Announces Chief Executive Officer Changes

Cann Group Limited Announces Final Clinical Trial Participant Completes Study

Less than half of directors are independent

Cann Group Limited Appoints Julian John Chick as Director

Cann Group Limited Announces Resignation of Peter Crock as CEO

Cann Group Limited Meets its Enrolment Target for Phase III Clinical Trial of Low-Dose Satipharm CBD Capsules for Short-Term Sleep Disturbance

Cann Group Limited Announces Executive Changes

Cann Group Limited Appoints Robert Barnes & Julian Chick to the Board

Cann Group Limited Announces Resignation of John Sharman as Director

Cann Group Limited, Annual General Meeting, Oct 25, 2022

Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)

Cann Group Limited Announce Therapeutic Goods Administration Grants Cann GMP License to Manufacture Therapeutic Goods

Cann Group Limited Receives Second Payment from Victorian Government's Regional Jobs Fund Program

Less than half of directors are independent

Office of Drug Control Grants Permit for Manufacture of Medicinal Cannabis Products to Cann Group Limited

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Cann Group Limited Announces Resignation of Mr. Geoffrey Pearce as Non-Executive Director

Cann Group Limited Announces Cann to Begin Recruitment for CBD Phase 3 Clinical Trial

Rua Bioscience Limited (NZSE:RUA) agreed to acquire 8.36% stake in Zalm Therapeutics Ltd from Cann Group Limited (ASX:CAN) for NZD 10 million.

Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For Now

Chief Financial Officer Greg Bullock has left the company

Full year 2021 earnings released: AU$0.097 loss per share (vs AU$0.12 loss in FY 2020)

Cann Group Limited Revises Revenue Guidance for the Year 2021

Cann Group Limited (ASX:CAN) completed the acquisition of Satipharm Ltd, Satipharm AG and Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT)

Cann Group Limited, Olivia Newton-John Cancer Research Institute and Austin Health Partnered in A Clinical Tria to Assess Medicinal Cannabis for Symptom Management in People with Advanced Cancer

Cann Group Limited (ASX:CAN) entered into a definitive sale agreement to acquire Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT).

First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.06 loss in 1H 2020)

Here's Why We're Not Too Worried About Cann Group's (ASX:CAN) Cash Burn Situation

Cann Group Limited (ASX:CAN) signed a share sale agreement to acquire Satipharm Ltd from Harvest One Cannabis Inc. (TSXV:HVT) for CAD 4 million.

New 90-day high: AU$0.78

Australis Capital Inc. and Cann Group Limited Sign Agreement

Price target lowered to AU$1.12

Cann Group Limited Receives Initial 19,000 Unit Order for Europe

What Type Of Returns Would Cann Group's(ASX:CAN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

One Forecaster Is Now More Bearish On Cann Group Limited (ASX:CAN) Than They Used To Be

Analysts update estimates

New 90-day high: AU$0.51

Deputy Chairman recently bought AU$55k worth of stock